Effect of fenretinide and low-dose tamoxifen on insulin sensitivity in premenopausal women at high risk for breast cancer

Harriet Johansson, Sara Gandini, Aliana Guerrieri-Gonzaga, Simona Iodice, Massimiliano Ruscica, Bernardo Bonanni, Marcella Gulisano, Paolo Magni, Franca Formelli, Andrea Decensi

Research output: Contribution to journalArticlepeer-review

Abstract

The prevalence of metabolic syndrome is increasing along with breast cancer incidence worldwide. Because fenretinide improves insulin action and glucose tolerance in insulinresistant obese mice and because tamoxifen has shown to regulate several markers involved in metabolic syndrome, we sought to investigate the effect of fenretinide or tamoxifen at low dose on features linked to insulin resistance in premenopausal women at risk for breast cancer. We randomized 235 women to low-dose tamoxifen (5 mg/daily), fenretinide (200 mg/daily), or their combination or placebo for 2 years. We used the homeostasis model assessment (HOMA; fasting insulin × glucose/22.5) to estimate insulin sensitivity. Women were considered to improve insulin sensitivity when they shifted from a HOMA ≥2.8 to

Original languageEnglish
Pages (from-to)9512-9518
Number of pages7
JournalCancer Research
Volume68
Issue number22
DOIs
Publication statusPublished - Nov 15 2008

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint

Dive into the research topics of 'Effect of fenretinide and low-dose tamoxifen on insulin sensitivity in premenopausal women at high risk for breast cancer'. Together they form a unique fingerprint.

Cite this